Jpmorgan Chase & CO Tricida, Inc. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.14 - $12.49 $20,671 - $1.84 Million	147,653 Added 666.54%	169,805 $26,000
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $15,513 - $24,792	1,823 Added 8.97%	22,152 $232,000
Q2 2022 Aug 11, 2022	SELL	$7.31 - $11.85 $164,898 - $267,312	-22,558 Reduced 52.6%	20,329 $196,000
Q1 2022 May 11, 2022	BUY	$7.35 - $10.63 $223,168 - $322,758	30,363 Added 242.44%	42,887 $353,000
Q4 2021 Feb 10, 2022	BUY	$4.19 - $9.56 $37,341 - $85,198	8,912 Added 246.73%	12,524 $120,000
Q3 2021 Nov 12, 2021	BUY	$3.56 - $4.64 $12,858 - $16,759	3,612 New	3,612 $17,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.